INIS
patients
100%
diseases
69%
antibodies
38%
inflammation
33%
data
29%
therapy
27%
safety
23%
proteins
20%
monitoring
16%
control
16%
immunity
16%
levels
15%
coronaviruses
15%
errors
15%
matrices
15%
biological markers
15%
hypertension
15%
covid-19
15%
comparative evaluations
12%
interstitials
12%
lungs
12%
adults
12%
plasma
10%
recommendations
10%
messenger-rna
10%
neutrophils
10%
guidelines
9%
genetics
9%
reviews
9%
risks
8%
vessels
7%
anemias
7%
allergy
7%
policy
7%
proliferation
7%
antibiotics
7%
plasma cells
7%
management
7%
drugs
7%
hyaluronidase
7%
immunoglobulins
7%
yields
7%
laboratories
7%
dynamics
6%
receptors
6%
cardiovascular diseases
6%
values
5%
genes
5%
mortality
5%
administration
5%
males
5%
mutations
5%
in vitro
5%
cell differentiation
5%
panels
5%
range
5%
Keyphrases
COVID-19
25%
Autoinflammatory Diseases
17%
Adverse Events
17%
Immunosuppressive Therapy
16%
Systemic Sclerosis
16%
Real-life Data
15%
Eurofever
15%
Clinical Response
15%
Humoral Response
15%
Breakthrough Infection
15%
Dephosphorylated Uncarboxylated Matrix Gla Protein
15%
Pulmonary Hypertension
15%
Interstitial Lung Disease
12%
CD38
11%
Immune-mediated Inflammatory Diseases
11%
Antibody Titer
10%
Anti-CD20
10%
Immune Response
9%
Evidence-based Recommendations
9%
Immunogenicity
9%
Dutch
8%
Disease-associated
8%
Large Vessel Vasculitis
7%
Inflammation
7%
Consensus Recommendations
7%
Antineutrophil Cytoplasmic Antibody
7%
Biomarker Potential
7%
Memory Response
7%
Vascular Inflammation
7%
Chronic Anemia
7%
Anti-CD38
7%
COVID-19 Vaccination Program
7%
Antibiotic Allergy
7%
Working Party
7%
Historical Overview
7%
Vascular Calcification
7%
Daratumumab
7%
B-cell Targeting
7%
Adult-onset Still's Disease
7%
VEXAS Syndrome
7%
Antibiotic Policy
7%
COVID-19 Booster Vaccination
7%
Inborn Errors of Immunity
7%
Clinical Follow-up
7%
Drug Dependence
7%
RNA Vaccination
7%
Breathomics
7%
Myositis-specific Antibodies
7%
Seroconversion
7%
Post-authorisation Studies
7%
Messenger RNA (mRNA)
7%
Long-term Safety
7%
Ocrelizumab
7%
HLA-DR
7%
Multiple Sclerosis
7%
Subcutaneous Immunoglobulin
7%
High Prevalence
7%
Hyaluronidase
7%
T Cell Activation Markers
7%
Systemic Immune-mediated Diseases
7%
Dilated Cardiomyopathy
7%
Genetic Landscape
7%
Vascular Remodeling
7%
Pulmonary Arterial Hypertension
7%
Antibody Repertoire
6%
β-lactam Antibiotics
5%
Cardiovascular Risk
5%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
26%
Immunology
17%
Humoral Immunity
17%
Breakthrough Infection
15%
Autoinflammatory Syndromes
15%
Immunosuppressant
15%
Immunosuppressive Drug
15%
CD38
15%
Primary Immunodeficiency
15%
COVID-19
15%
CD20
13%
B Cell
9%
Blood Plasma
9%
Prevalence
9%
Antibody Titer
8%
Dynamics
8%
Immune-Mediated Inflammatory Diseases
8%
T Cell Activation
8%
Autoantibodies
8%
Immunity
8%
Cross Allergy
7%
Medical Dictionary for Regulatory Activities
7%
Immunogenicity
7%
Decision Making
7%
Delayed Hypersensitivity
7%
Vasculitis
7%
Neutrophil Cytoplasmic Antibody
7%
Systemic Scleroderma
7%
Hypersensitive Response
7%
Daratumumab
7%
Adult-Onset Still's Disease
7%
Ocrelizumab
7%
Myositis
7%
Seroconversion
7%
Multiple Sclerosis
7%
HLA-DR
7%
Vaccination
7%
Neurological System
7%
Colchicine
7%
Whole Exome Sequencing
7%
Isotype
6%
Omicron Coronavirus Variant
5%